Price increases threatening the availability of EpiPen® and EpiPen Jr® Auto-Injectors (“EpiPen”) have touched off the latest firestorm over drug pricing. Lost amid the public outcry, however, is a thorny regulatory issue: EpiPen’s classification as a generic drug for purposes of the Medicaid Drug Rebate Program (“MDRP”). Resolution of the classification issue carries significant risk for segments of … Continue reading this entry
Tags: Centers for Medicare & Medicaid Services, epipen, Medicaid, mylan